This page shows the latest HPP news and features for those working in and with pharma, biotech and healthcare.
A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still
New deal offers NHS England a discount for the drug. More babies with the rare and life-threatening disease paediatric-onset hypophosphatasia (HPP) will be able to get access to ... There are up to seven cases of HPP diagnosed every year in England, and
asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.
The National Institute for Health and Care Excellence (NICE) has said evidence for the drug's benefits in paediatric-onset hypophosphatasia (HPP) - a rare, inherited disorder of the bones - is not ... pain. There are around seven cases of HPP diagnosed
David Hallal, CEO of Alexion, said: “The CHMP positive opinions for Strensiq and Kanuma are significant milestones in bringing these therapies to infants, children, and adults suffering from HPP and ... Both Strensiq and Kanuma are highly innovative
It is however hoping to add a second from its own stable later this year - Strensiq (asfotase alfa) for hypophosphatasia (HPP) - as well as Kanuma (sebelipase alfa) for lysosomal acid lipase
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
No results were found
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...